Arthur Klausner

Arthur J.
Klausner was the founder of Goldilocks Therapeutics, Inc., founded in 2018, where the titles held included President, Chief Executive Officer & Director from 2018 to 2022.
Current jobs include President & Chief Executive Officer at Delphinus Therapeutics, Inc. since 2018; Executive Chairman at Concarlo Holdings LLC; Non-Independent Non-Executive Director at Cennerv Pharmaceuticals Ltd. since 2015; Director at Amyriad Therapeutics, Inc.; Director at NYU Langone Health; and Director at NYU Innovation Venture Fund.
Former jobs include Chief Executive Officer & Director at Gem Pharmaceuticals LLC from 2012 to 2017; Chief Executive Officer at Jade Therapeutics, Inc. from 2012 to 2015; Director roles at Santarus, Inc., Orexigen Therapeutics, Inc., Syndax Pharmaceuticals, Inc., X-Ceptor Therapeutics, Inc., Gentis, Inc., and Monopar Therapeutics, Inc. (Independent Director); and Partner at Pappas Capital LLC from 2005 to 2009.
Education includes undergraduate studies at Princeton University and an MBA from Stanford Graduate School of Business.